Brief: Egetis Therapeutics FY Revenue At SEK 62.3 Million, Below IBES Estimate

Egetis Therapeutics AB (publ)

26/02/2026 06:23

Feb 26 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST:

FY REVENUE SEK 62.3 MILLION VERSUS. IBES ESTIMATE SEK 67.2 MILLION

FY NET INCOME SEK -342.5 MILLION

FY ADJUSTED EPS SEK -0.9

OUTLOOK: WORK CLOSELY WITH FDA DURING REVIEW OF EMCITATE NDA, WITH GOAL OF APPROVAL IN SECOND HALF OF 2026

OUTLOOK: SUCCESSFULLY LAUNCHING EMCITATE IN U.S. IN Q4 2026

OUTLOOK: CONTINUING ROLLOUT OF EMCITATE IN EUROPE IN 2026

Source text: ID:nMFN8YCzb5

Further company coverage: EGTX.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))